Background {#Sec1}
==========

About a quarter of the world's population were estimated to be latently infected with *Mycobacterium tuberculosis* (*M.tb*) \[[@CR1]\]. It was estimated that 5--10% infections might develop active tuberculosis (TB) during their lifetime \[[@CR2], [@CR3]\]. Scaling up latent tuberculosis infection (LTBI) testing and treatment among individuals at high-risk of developing active disease is a critical priority action for the END TB \[[@CR4]--[@CR6]\]. Currently, directly observe the decline of incidence is the standard way to evaluate the protective effect of the preventive treatment, which usually needs a long follow-up period and huge resource input. Tuberculin Skin Test (TST) and Interferon-γ Release Assays (IGRAs) both are immunological tests to identify infections, but they are poor at predicting the development of active disease \[[@CR7], [@CR8]\]. Accessible surrogate biomarkers could reflect the effectiveness of LTBI treatment are warranted in the era of prevention centered.

It has been recognized that cytokines and chemokines play important roles in shaping immunity against TB by polarizing T cell subsets responses, modulating immune cell trafficking, and regulating inflammatory responses \[[@CR9]\]. Some exploratory studies evaluated specific antigen stimulated or un-stimulated serum cytokine biomarkers other than IFN-γ for monitoring the potential effect of anti-TB treatment, such as TNF-α, IL-10, IL-6, IL-1ra, MIP-1β, IL-2/IFN-γ and IP-10 \[[@CR10]--[@CR14]\]. Nevertheless, few studies have been conducted to assess the performance of un-stimulated serum cytokine levels in monitoring host response to preventive treatment of LTBI \[[@CR12]\]. Therefore, the aim of the present study was to identify potential cytokine biomarkers associated with prophylactic treatment which might also predict the development of TB from LTBI.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Study participants in current study were selected from a randomized controlled trial (RCT) exploring short-course treatment regimen for 50--70 years rural residents with LTBI in China. Detailed information of the trial has been published elsewhere \[[@CR6]\]. Briefly, all participants aged 50 to 70 years old with QuantiFERON TB Gold In-Tube (QFT, Qiagen, USA) positive result (TB Ag-Nil ≥0.35 IU/ml) and without current active TB at baseline survey were included for a RCT. They were randomly classified into three groups (Group A: 8 weeks regimen of once-weekly RPT plus INH, between 7 November 2015 and 2 January 2016; Group B: 6 weeks of twice-weekly RPT plus INH, between 25 November 2015 and 2 January 2016; Group C: untreated controls). During the 2-year follow-up after the preventive treatment, a total of 30 incident cases of active TB were diagnosed. Among them, 21 active TB cases (Group A = 8; Group B = 4; Group C = 9) with available blood samples and who completed the assigned regimes were included in current study. In addition, 42 gender and age matched non-TB subjects (Group A = 16; Group B = 8; Group C = 18) were included in the present study as well. The protocol of the present study has been approved by the Ethics Committees of the Institute of Pathogen Biology, Chinese Academy of Medical Sciences (IDs: IPB-2015-5 and IPB-2016-8). All participants have signed the written informed consent.

Cytokines measurements {#Sec4}
----------------------

Blood samples at baseline (T0, 1 week before starting treatment) and at the end of preventive treatment (T1, 1 week after completing the treatment) have been collected and retained. Ready-made cytokine Kit (Bio-Rad Laboratories, Hercules, CA, USA) which could simultaneously detect forty-eight cytokines (CTACK, Eotaxin, GRO-α, interferon-inducible protein (IP)-10/CXCL10, macrophage chemoattractant protein (MCP-1)/MCAF, MCP-3, MIF, MIG, macrophage inflammatory protein-1α (MIP-1α), MIP-1β, PDGF-BB, RANTES, SDF-1α, granulocyte macrophage colony stimulating factor (GM-CSF), G-CSF, SCF, M-CSF, VEGF-A, LIF, Basic FGF, HGF, β-NGF, SCGF-β, IFN-α2, IFN-γ, tumor necrosis factor (TNF)-α, TNF-β, TRAIL, Interleukin (IL)-1α, IL-1β, IL-1ra, IL-2Rα, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-12(p40), IL-13, IL-15, IL-16, IL-17A and IL-18) were used. Levels of the selected cytokines were determined for each undiluted and un-stimulated serum sample (50 μl) by magnetic bead suspension array using the Bio-Plex Pro Human Cytokine panels according to the manufacturer's instructions. Cytokines with \> 50% of the samples below the lower detection level (LDL) of the assay will be excluded from further statistical analysis. Additionally, cytokines with occasional values (\< 50%) below the LDL were assigned an averaged value between 0 and the lowest detectable level in each assay plate \[[@CR15]\].

Statistical analysis {#Sec5}
--------------------

Statistical analyses were performed using SAS 9.4 version (SAS institute, Cary, NC) and GraphPad Prism 5 (GraphPad software, San Diego, CA). Participants who completed ≥90% doses of the therapy were defined as completed the regimes. The Chi-square and Fisher's exact tests were used to compare the distribution of categorical variables across groups. The level of cytokines was presented with median (Q25-Q75). Wilcoxon rank sum test was used to compare cytokine responses between different participants at the same time-point. Wilcoxon signed rank test was used to evaluate the cytokine responses for the same person at different time points. To assess the predictive ability of the cytokines, receiver operating characteristic (ROC) analysis was conducted and the area under ROC curves (AUCs) was calculated. Sensitivities and specificities were also calculated using the value with the highest Youden Index as the cut-off. A two-tailed *p*-value \< 0.05 was considered statistically significant.

Results {#Sec6}
=======

Characteristics of the study participants {#Sec7}
-----------------------------------------

Table [1](#Tab1){ref-type="table"} shows major characteristics of the study participants. For both treated and untreated participants, no significant difference was found between active TB and non-TB groups with respect to gender, age, fasting blood glucose and QFT results. However, active TB patients had lower median body mass index (BMI) level (22.46 kg/m^2^) than non-TB controls (25.53 kg/m^2^) among untreated participants (*p* = 0.029). At baseline, active TB patients showed a trend with higher proportion of IFN-γ values ≥0.70 IU/ml than non-TB controls, but such a difference was not statistically significant. Table 1Characteristics of the participants included in the studyTreated participantsUntreated controlsDeveloped active TB during follow-upKept healthy during follow-up*p* valueDeveloped active TB during follow-upKept healthy during follow-upp valueTotal^a^1224918Median age (Q25-Q75) (years)69.00 (65.00, 72.50)69.00 (65.00, 73.00)0.973^b^67.00 (62.00, 70.00)67.00 (62.00, 70.00)0.979^b^Gender, n (%)1.000^c^1.000^d^ Male6 (50.00)12 (50.00)7 (77.78)14 (77.78) Female6 (50.00)12 (50.00)2 (22.22)4 (22.22)Median BMI (Q25-Q75) (Kg/m^2^)23.54 (19.67, 26.66)24.11 (21.71, 27.25)0.535^b^22.46 (20.69, 23.88)25.53 (21.81, 28.00)0.029^b^Fasting blood glucose, n (%)0.253^d^0.539^d^ ≥7.0 mmol/L2 (16.67)1 (4.17)0 (0.00)2 (11.11) \<7.0 mmol/L10 (83.33)23 (95.83)9 (100.00)16 (88.89)Median INF-γrelease of QFT (Q25-Q75) (IU/ml) T02.47 (1.76, 5.06)2.79 (0.90, 4.81)0.651^b^2.06 (1.52, 2.81)1.50 (0.92, 3.29)0.520^b^ T11.52 (0.91, 3.30)0.87 (0.18, 1.91)0.095^b^0.73 (0.63, 1.06)0.63 (0.23, 1.51)0.471^b^Classified QFT results at T0 (IU/ml), n (%) 0.35 \~ 0.700 (0.00)4 (16.67)0.279^d^1 (11.11)4 (22.22)0.636^d^ ≥0.7012 (100.00)20 (83.33)8 (88.89)14 (77.87)*Abbreviation*: *BMI* body mass index, *Q25* 25% quantile, *Q75* 75% quantile, *QFT* QuantiFERON-TB Gold In-Tube, *TB* tuberculosis, *T0* baseline, *T1* At the end of preventive treatment. ^a^Data might not sum to total because of missing data^b^p for Wilcoxon rank sum test. ^c^ p for χ^2^ test. ^d^p for Fisher's exact test

Serum cytokine levels in treated and untreated participants at T0 {#Sec8}
-----------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} showed the baseline median level of cytokines among participants with and without TB occurrence classified by preventive treatment**.** The levels of 10 tested cytokines (LIF, TNF-β, IL-2, IL-3, IL-5, IL-7, IL-10, IL-12(p70), IL-12(p40) and IL-15) were below the LDL, they were not included for further data analysis. Table 2Median serum levels of selected cytokines among participants with and without TB occurrence classified by preventive treatment at T0 (Median \[Q25-Q75\] (pg/ml))CytokinesUntreated controlsTreated participantsActive TB (*n* = 9)Non-TB (*n* = 18)P for Wilcoxon rank sum testActive TB (*n* = 12)Non-TB (*n* = 24)P for Wilcoxon rank sum testCTACK317.71 (247.15, 392.20)339.63 (288.62, 381.48)0.817245.16 (183.03, 342.38)340.84 (260.21, 385.66)0.164Eotaxin86.14 (56.31, 100.06)34.46 (29.40, 37.82)**\< 0.001**69.18 (58.08, 87.05)37.14 (26.61, 66.58)**0.008**GRO-α88.03 (74.31, 136.90)79.17 (69.80, 84.97)0.227113.26 (100.91, 130.08)69.82 (55.58, 89.86)**\< 0.001**IP-10564.61 (372.63, 670.62)373.06 (329.38, 525.68)0.173514.05 (380.24, 606.51)438.45 (351.99, 499.43)0.275MCP-1(MCAF)12.60 (9.20, 16.31)6.81 (5.14, 9.74)**0.017**14.08 (10.57, 20.05)7.91 (5.65, 10.10)**\< 0.001**MCP-31.15 (0.30, 1.96)0.83 (0.42, 1.07)0.7381.78 (0.45, 3.59)0.80 (0.43, 1.70)0.354MIF305.23 (227.36, 405.16)282.69 (255.65, 348.78)0.396318.45 (195.43, 358.95)271.78 (220.06, 312.82)0.322MIG356.29 (308.93, 590.65)285.33 (179.67, 366.12)0.129371.04 (226.06, 612.31)308.06 (214.66, 428.46)0.430MIP-1α1.35 (1.17, 1.82)1.18 (0.95, 1.35)0.1001.47 (1.41, 1.85)1.32 (0.94, 1.51)0.024MIP-1β48.10 (38.42, 57.29)38.03 (33.57, 43.83)**0.048**50.75 (47.05, 63.37)38.06 (30.83, 44.48)**\< 0.001**PDGF-BB64.30 (42.51, 198.85)84.51 (26.05, 114.55)0.425146.33 (98.52, 232.85)43.91 (26.70, 71.55)**0.001**RANTES1314.40 (677.29, 1607.11)1134.09 (467.87, 1437.52)0.4881194.57 (839.53, 2194.69)762.83 (468.35, 1217.44)0.050SDF-1α268.74 (253.62, 357.07)219.86 (181.17, 275.33)**0.017**309.99 (234.09, 339.68)211.88 (190.64, 251.72)**0.008**SCF37.10 (27.55, 46.29)47.10 (32.85, 55.57)0.45642.94 (28.96, 50.35)40.35 (26.53, 56.04)0.960M-CSF33.51 (25.14, 38.47)35.26 (26.15, 49.94)0.70031.64 (22.22,42.16)37.66 (27.04, 50.64)0.275G-CSF70.18 (68.86, 89.17)45.96 (39.89, 52.46)**0.001**89.49 (73.15, 97.55)49.40 (36.56, 62.44)**\< 0.001**GM-CSF0.79 (0.61, 1.25)0.60 (0.01, 1.13)0.2551.03 (0.70, 2.37)0.77 (0.14, 1.33)0.122VEGF-A30.46 (19.20, 52.30)10.62 (3.37, 15.07)**0.006**46.18 (38.72, 62.85)13.34 (3.37, 23.12)**\< 0.001**Basic FGF19.51 (19.51, 27.46)9.91 (7.71, 11.27)**\< 0.001**23.62 (20.22, 25.25)11.60 (7.52, 17.13)**\< 0.001**β-NGF0.74 (0.38, 0.92)0.47 (0.15, 0.74)0.2260.88 (0.74, 1.51)0.56 (0.28, 0.74)**0.002**SCGF-β43,169.60 (38,013.20, 57,726.50)40,842.80 (25,219.40, 45,309.10)0.31643,618.70 (38,251.70, 50,595.10)41,198.40 (34,222.50, 49,973.30)0.513HGF256.86 (249.02,352.46)227.92 (173.75, 340.78)0.292245.12 (213.87, 301.36)229.34 (160.76, 297.97)0.557IFN-α25.61 (4.07, 9.52)4.35 (2.73, 4.90)0.0608.14 (6.93, 10.77)4.71 (2.95, 5.85)**\< 0.001**IFN-γ26.08 (18.59,31.97)9.48 (8.21, 14.39)**\< 0.001**20.89 (17.76, 33.82)14.41 (9.16, 16.86)**\< 0.001**TNF-α13.98 (12.53,16.84)9.60 (6.47,13.04)**0.009**15.89 (14.22, 17.78)8.97 (7.94, 12.41)**\< 0.001**TRAIL35.54 (34.96,55.72)28.38 (20.62, 33.46)**0.002**40.94 (35.11, 44.48)32.11 (30.12, 38.04)**0.019**IL-1α9.96 (8.44, 11.48)4.23 (1.86, 4.92)**\< 0.001**16.45 (11.86, 22.98)5.51 (3.21, 7.47)**\< 0.001**IL-1β2.90 (2.17, 3.26)1.88 (1.40, 3.69)0.3162.16 (1.59, 3.41)2.10 (1.38, 2.97)0.603IL-1ra164.78 (145.93, 185.71)70.70 (55.80, 128.01)**0.004**173.64 (157.39, 185.69)107.36 (80.87, 150.82)**\< 0.001**IL-2Rα99.66 (83.29, 122.15)95.46 (76.73, 141.57)0.85776.25 (47.30, 115.92)101.79 (67.09, 133.93)0.268IL-42.18 (2.01, 2.59)0.35 (0.17, 0.51)**\< 0.001**2.34 (1.94, 3.01)0.52 (0.39, 1.42)**\< 0.001**IL-60.91 (0.56, 1.63)0.65 (0.16, 0.93)0.2461.39 (1.01,2.45)0.91 (0.26, 1.25)**0.021**IL-84.75 (3.46, 6.61)2.28 (1.57, 3.16)**0.003**6.04 (4.40, 7.19)3.14 (2.15, 4.36)**\< 0.001**IL-958.55 (51.44, 65.08)29.50 (26.06, 32.90)**0.001**65.00 (53.56, 69.74)30.86 (24.88, 41.36)**\< 0.001**IL-133.70 (2.31, 3.92)1.94 (1.14, 5.21)0.4402.79 (2.00, 4.69)2.23 (1.59, 4.70)0.314IL-1641.51 (40.09, 49.67)32.48 (28.14, 53.88)0.34137.98 (22.49, 52.19)32.30 (25.81, 41.78)0.535IL-17A5.12 (4.50, 5.90)2.47 (1.16, 3.73)**0.013**6.68 (6.05, 8.09)3.90 (2.39, 5.12)**\< 0.001**IL-1841.61 (35.17, 57.57)40.37 (30.12, 102.04)0.85733.54 (26.08, 42.52)29.43 (24.75, 58.68)0.801*Abbreviation*: *T0* baseline, *Q25* 25% quantile, *Q75* 75% quantile, *TB* tuberculosis

The levels of 16 cytokines including Eotaxin, MCP-1(MCAF), SDF-1α, MIP-1β, G-CSF, VEGF-A, Basic FGF, IFN-γ, TNF-α, TRAIL, IL-1α, IL-1ra, IL-4, IL-8, IL-9 and IL-17A were significantly higher in active TB patients compared with non-TB controls in both untreated and treated participants at T0. No significant difference was found for the serum levels of the rest 22 cytokines no matter whether preventative treatment conducted.

Performance of the 16 cytokines in predicting active TB development {#Sec9}
-------------------------------------------------------------------

To further evaluate the performance on predicting active TB, the AUCs were calculated among untreated participants at T0 (Table [3](#Tab3){ref-type="table"}). Ten cytokines were found to have an AUC \> 0.85 (Eotaxin = 0.95, Basic FGF = 0.96, G-CSF = 0.89, IFN-γ = 0.95, IL-1α = 0.92, IL-1ra = 0.85, IL-4 = 1.00, IL-8 = 0.86, IL-9 = 0.90 and TRAIL = 0.88) (Table [3](#Tab3){ref-type="table"}). Table 3Predicting value of the baseline (T0) serum cytokines levels on active TB development among untreated controlsCytokineAUC (95%CI)p for *z*-testCut-off (pg/ml)Sensitivity,% (95% CI)Specificity,% (95% CI)Eotaxin0.95 (0.87, 1.03)**\<0.001**50.5488.89 (51.75, 99.72)94.44 (72.71, 99.86)Basic FGF0.96 (0.88, 1.02)**\<0.001**17.4988.89 (51.75, 99.72)94.44 (72.71, 99.86)G-CSF0.89 (0.76, 1.02)**0.001**58.8988.89 (51.75, 99.72)88.89 (65.29, 98.62)IFN-γ0.95 (0.87, 1.03)**\<0.001**17.4188.89 (51.75, 99.72)94.44 (72.71, 99.86)IL-1α0.92 (0.82, 1.02)**0.001**8.0688.89 (51.75, 99.72)88.89 (65.29, 98.62)IL-1ra0.85 (0.70, 1.00)**0.003**114.70100.00 (66.37, 100.00)72.22 (46.52, 90.31)IL-41.00 (1.00, 1.00)**\<0.001**1.16100.00 (66.37,100.00)100.00 (81.47,100.00)IL-80.86 (0.73, 1.00)**0.002**3.4477.78 (39.99, 97.19)83.33 (58.58, 96.42)IL-90.90 (0.77, 1.04)**0.001**38.8588.89 (51.75, 99.72)94.44 (72.71, 99.86)IL-17A0.80 (0.63, 0.98)**\<0.001**3.48100.00 (66.37, 100.00)72.22 (46.52, 90.31)MCP-1(MCAF)0.79 (0.59, 0.99)**0.016**10.3466.67 (29.93, 92.51)83.33 (58.58, 96.42)MIP-1β0.75 (0.55, 0.94)**0.040**57.6555.56 (21.20, 86.30)94.44 (72.71, 99.86)SDF-1α0.79 (0.61, 0.97)**0.016**218.00100.00 (66.37, 100.00)50.00 (26.02, 73.98)TNF-α0.82 (0.66, 0.97)**0.009**10.48100.00 (66.37, 100.00)61.11 (35.75, 82.70)TRAIL0.88 (0.74, 1.01)**0.002**34.5177.78 (39.99, 97.19)88.89 (65.29, 98.62)VEGF-A0.83 (0.66, 1.00)**0.006**14.3188.89 (51.75, 99.72)72.22 (46.52, 90.31)*Abbreviation*: *AUC* area under curve, *TB* tuberculosis

Serum levels of the 16 selected cytokines in different time-points {#Sec10}
------------------------------------------------------------------

In treated participants, as compared with level at T0, statistically significant reductions were found for serum levels of Eotaxin, SDF-1α, Basic FGF, IFN-γ, IL-1ra, IL-4 and IL-8 in active TB group at T1. For non-TB group, as compared with T0, there were statistically significant decreases in serum levels of Eotaxin, SDF-1α, TRAIL, IL-1ra and IL-8 while increases for MIP-1β and IL-9 (Table [4](#Tab4){ref-type="table"}). Table 4Median serum levels of the selected cytokines at different time point in participants with and without preventive treatment respectively^a^CytokineActive TBNon-TBT0T1p for Wilcoxon signed rank testT0T1p for Wilcoxon signed rank testMedian value (Q25-Q75) (pg/ml) in treated participants (active TB, n = 12; non-TB, n = 24) Eotaxin69.18 (58.08, 87.05)45.18 (36.09,75.64)**0.021**37.14 (26.61, 66.58)33.34 (22.22, 48.22)**0.010** MCP-1(MCAF)14.08 (10.57, 20.05)11.60 (9.68, 15.26)0.0527.91 (5.65, 10.10)7.38 (5.01, 12.86)0.300 MIP-1β50.75 (47.05, 63.37)56.63 (50.95, 61.09)0.47038.06 (30.83, 44.48)49.03 (44.11, 54.68)**\< 0.001** SDF-1α309.99 (234.09, 339.68)229.56 (203.70, 261.91)**0.007**211.88 (190.64, 251.72)177.85 (158.87, 220.24)**0.008** G-CSF89.49 (73.15, 97.55)71.50 (60.18, 85.92)0.11049.40 (36.56, 62.44)65.14 (39.89, 78.41)0.040 VEGF-A46.18 (38.72, 62.85)42.22 (28.75, 52.27)0.33913.34 (3.37, 23.12)6.43 (0.25, 37.39)0.187 Basic FGF23.62 (20.22, 25.25)19.51 (18.79, 21.27)**0.010**11.60 (7.52, 17.13)11.28 (6.52, 20.05)0.459 IFN-γ20.89 (17.76, 33.82)19.74 (12.71, 26.54)**0.021**14.41 (9.16, 16.86)13.87 (5.52, 16.82)0.320 TNF-α15.89 (14.22, 17.78)15.41 (12.66, 17.78)0.3498.97 (7.94, 12.41)10.36 (6.77, 13.98)0.478 TRAIL40.94 (35.11, 44.48)36.59 (36.42, 43.32)0.73332.11 (30.12, 38.04)31.28 (23.18, 37.34)**0.037** IL-1α16.45 (11.86, 22.98)13.01 (10.72, 14.53)0.0155.51 (3.21, 7.47)5.24 (1.52, 14.53)0.129 IL-1ra173.64 (157.39, 185.69)126.44 (114.19, 133.83)**0.002**107.36 (80.87, 150.82)95.66 (55.77, 131.74)**0.009** IL-42.34 (1.94, 3.01)1.61 (1.36, 2.01)**0.013**0.52 (0.39, 1.42)0.64 (0.04, 1.55)0.575 IL-86.04 (4.40, 7.19)4.05 (3.58, 4.64)**0.017**3.14 (2.15, 4.36)2.04 (0.70, 3.34)**\< 0.001** IL-965.00 (53.56, 69.74)63.83 (55.94, 77.15)0.73330.86 (24.88, 41.36)37.00 (31.20, 64.25)**\< 0.001** IL-17A6.68 (6.05, 8.09)5.74 (5.05, 6.21)0.0343.90 (2.39, 5.12)2.97 (0.57, 5.90)0.187Median value (Q25-Q75) (pg/ml) in untreated controls (active TB, n = 9; non-TB, n = 18) Eotaxin86.14 (56.31, 100.06)55.38 (39.96, 59.73)**0.012**34.46 (29.40, 37.82)28.43 (21.67, 38.27)0.265 MCP-1(MCAF)12.60 (9.20, 16.31)12.17 (11.41, 14.12)0.5706.81 (5.14, 9.74)6.88 (5.14, 10.16)0.212 MIP-1β48.10 (38.42, 57.29)57.68 (49.97, 59.57)0.30138.03 (33.57, 43.83)48.19 (35.40, 54.16)**0.024** SDF-1α268.74 (253.62, 357.07)223.75 (205.00, 256.94)**0.039**219.86 (181.17, 275.33)175.13 (142.03, 225.55)**0.027** G-CSF70.18 (68.86, 89.17)78.74 (64.20, 94.98)0.82045.96 (39.89, 52.46)52.17 (32.71, 62.19)0.304VEGF-A30.46 (19.20, 52.30)27.04 (14.41, 35.17)0.49610.62 (3.37, 15.07)13.88 (0.25, 27.04)0.426Basic FGF19.51 (19.51, 27.46)19.51 (18.06, 20.92)0.0559.91 (7.71, 11.27)11.98 (6.93, 15.78)0.186IFN-γ26.08 (18.59,31.97)20.47 (14.40,26.28)0.0559.48 (8.21, 14.39)9.52 (4.75, 15.24)0.702TNF-α13.98 (12.53,16.84)14.46 (11.81,16.84)0.6889.60 (6.47,13.04)9.00 (5.07, 11.08)0.246TRAIL35.54 (34.96,55.72)40.35 (38.76,42.93)0.82028.38 (20.62, 33.46)25.86 (18.61, 32.15)0.694IL-1α9.96 (8.44, 11.48)11.48 (7.68, 14.53)0.7424.23 (1.86, 4.92)4.32 (1.52,9.96)0.096IL-1ra164.78 (145.93, 185.71)116.49 (111.89, 129.64)0.07870.70 (55.80, 128.01)89.36 (40.01, 109.54)0.265IL-42.18 (2.01, 2.59)1.67 (1.42, 1.87)**0.027**0.35 (0.17, 0.51)0.58 (0.05, 1.16)0.072IL-84.75 (3.46, 6.61)3.81 (3.22, 4.05)**0.047**2.28 (1.57, 3.16)1.91 (0.84, 2.39)**0.030**IL-958.55 (51.44, 65.08)66.41 (58.89, 69.24)0.49629.50 (26.06, 32.90)35.55 (23.97, 64.91)**0.003**IL-17A5.12 (4.50, 5.90)5.43 (4.50, 6.05)0.5782.47 (1.16, 3.73)3.12 (1.16, 4.19)0.832*Abbreviation*: *T0* baseline, *T1* At the end of preventive treatment; *Q25* 25% quantile, *Q75* 75% quantile, *TB* tuberculosis^a^ Those cytokines, which had a significantly higher level in active TB individuals compared with non-TB controls at T0 were selected

In untreated participants, as compared with level at T0, statistically significant reductions in serum levels of Eotaxin, SDF-1α, IL-4 and IL-8 were found in active TB group at T1. For non-TB group, as compared with T0, there were statistically significant decreases in serum levels of SDF-1α and IL-8 while increases for MIP-1β and IL-9 (Table [4](#Tab4){ref-type="table"}).

As shown in Fig. [1](#Fig1){ref-type="fig"}, only the median level of IL-1ra declined significantly from T0 (173.64 IU/ml) to T1 (126.44 IU/ml) in active TB group (*p* = 0.002) and from T0 (107.36 IU/ml) to T1 (95.66 IU/ml) in non-TB group (*p* = 0.009) among treated participants. No statistically significant difference was found for IL-1ra level at T1 as compared with T0 both in active TB and non-TB groups among untreated participants (*p* = 0.078 for active TB group, *p* = 0.265 for non-TB group) (Table [4](#Tab4){ref-type="table"}). Fig. 1Flow chart to identify the relation between serum cytokines level and preventive treatment efficacy. A total of 12 active TB cases and 24 non-TB individuals from treated participants as well as 9 active TB cases and 18 non-TB individuals from untreated controls, paired by gender and age, were included in the present study. The levels of 16 cytokines were significantly higher in active TB cases as compared with non-TB controls both in treated participants and untreated controls at T0. Only the level of IL-1ra declined significantly from T0 to T1 in treated participants, but not in untreated controls

Discussion {#Sec11}
==========

Our results provided new insight into using serum cytokines as biomarkers to evaluate host responses to LTBI preventative treatment. The baseline serum levels of 16 cytokines were found to be significantly higher in those developed active TB laterly as compared with non-TB controls in both untreated and treated participants. Among them, in particular, IL-1ra responses declined significantly after treatment in treated participants, suggesting a predisposing role as biomarker to predict the development of active TB.

To our knowledge, only a handful of studies ever explored the relationship between cytokines and TB development. A study from Amsterdam cohort reported that the expression of IL-13 could predict the development of TB within months before the onset of clinical symptoms among HIV-infected individuals \[[@CR16]--[@CR18]\]. Another prospective study found that IP-10 levels in active patients were higher than in household and community controls \[[@CR19]\]. A subsequent study conducted in participants with HIV-TB and active TB made similar observations, which reported that blood IP-10 levels were significantly higher in active TB patients than in controls, regardless of HIV infection \[[@CR20]\]. Such previous findings were not observed in our study, different demographic and clinical characteristics of the study participants and different time points selected for cytokine measurements might result in the inconsistence. As most of the previous studies compared the level of cytokines between active TB patients and LTBI participants through case-control design, the influence of individual difference within group on the cytokines response could not be excluded \[[@CR21]--[@CR25]\]. Our longitudinal cohort-based study provides more solid evidence using dynamic changes of the serum cytokines in the same person. However, study with large samples size are needed to verify the current result.

Our study showed that the level of IL-1ra declined significantly during therapy both in active TB and non-TB groups. But such a difference was not observed for untreated participants. It was consistent with a prospective study which observed a statistically significant decline in IL-1ra responses at 6 and 9 months after treated with isoniazid for 9 months in participants with LTBI \[[@CR12]\]. Our results showed the decline occurred as early as 1 week after the treatment, which suggested a possibility that IL-1ra level might be used for real-time treatment effect monitoring. IL-1ra is a cytokine produced by monocytes, macrophages, and dendritic cells, which prevents the binding of IL-1α as well as IL-1β to IL-1R1 by competitively blocking IL-1RI receptors \[[@CR26], [@CR27]\]. IL-1ra expression played an important role during mycobacterial antigen-elicited granuloma formation, an immune and physical barrier to contain the infection and prevent MTB dissemination \[[@CR28], [@CR29]\]. A prospective study conducted in active TB cases found that serum IL-1ra concentrations were significantly reduced after anti-TB treatment and the level of IL-1ra was higher in patients with delayed treatment response than those with good response to therapy \[[@CR30]\]. These studies consistently suggested that IL-1ra might be potential correlates of successful treatment in both active TB and LTBI individuals. Our results provide novel insight into using IL-1ra as an early prognosis biomarker to evaluate the performance of the preventive treatment. Besides, it was recently reported that *M.tb*-infected mice receiving anti-IL-1ra antibody had significantly lower bacterial burdens in their lungs as compared to PBS-treated controls \[[@CR31]\]. Additionally, patients with rheumatic diseases receiving monoclonal IL-1ra antibodies had a significantly increased risk of TB re-activation \[[@CR32]\]. These findings provide further evidence to support the relation between higher levels of baseline IL-1ra and the risk of developing active TB observed in our study. However, cytokine measurements were not repeated at the time of diagnosis of active TB in our study, whether serum level of IL-1ra could differentiate active TB and LTBI needs to be further verified.

When interpreting the results of the study, some limitations should be kept in mind. First, although we used the same Luminex kit to test serum samples collected at different time points, the influence of storage time on sample quality could not be completely ruled out. Second, considering the feasibility of monitoring peripheral blood cytokines after preventive treatment un-stimulated serum samples were measured in our study. Therefore, the dynamic change of cytokine concentrations observed in our study might could not accurately reflect the changes in immune levels caused by TB-specific pathogens. Our results needs to be verified by further study with larger sample size and with specific antigen stimulated samples \[[@CR33]\]. Third, due to the limited sample size, we pooled the treated participants who were treated with different regimens for analysis, which might have an impact on the outcomes. Fourth, as the RCT targeting elder population with attenuation of immunity, generalization of the study results should be cautious. Fifth, in order to avoid potential confounding effect, controls not developed active TB were matched with cases by age and gender, but bias caused by other potential confounders could not be excluded in our study \[[@CR6]\].

Conclusions {#Sec12}
===========

Our results suggested that serum level of IL-1ra decreased along with preventive treatment and might be used to predict disease progression. It provided a clue for exploring prognosis biomarkers to evaluate the performance of LTBI treatment, but our findings needs further verification by studies with larger sample size in different populations.

LTBI

:   Latent tuberculosis infection

TB

:   Tuberculosis

*M.tb*

:   *Mycobacterium tuberculosis*

TST

:   Tuberculin skin test

IGRAs

:   Interferon-γ Release Assays

QFT

:   QuantiFERON TB Gold In-Tube

IP-10

:   Interferon-inducible protein − 10

MCP-1

:   Macrophage chemoattractant protein-1

MIP-1α

:   Macrophage inflammatory protein-1α

GM-CSF

:   Granulocyte macrophage colony stimulating factor

ROC

:   Receiver operating characteristic

AUCs

:   Area under ROC curves
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